An Open-label Phase 2 Study to Evaluate the Safety and Immnogenicity of a Single Subcutaneous Injection of Quadrivalent TAK-850 in Healthy Adult Subjects

Trial Profile

An Open-label Phase 2 Study to Evaluate the Safety and Immnogenicity of a Single Subcutaneous Injection of Quadrivalent TAK-850 in Healthy Adult Subjects

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2016

At a glance

  • Drugs TAK 850 (Primary)
  • Indications Influenza A virus infections; Influenza B virus infections; Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Takeda
  • Most Recent Events

    • 24 Aug 2016 Status changed from active, no longer recruiting to withdrawn prior to enrolment.
    • 22 Apr 2016 Status changed from not yet recruiting to active, no longer recruiting.
    • 22 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top